125 related articles for article (PubMed ID: 18441450)
1. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.
Hongo M; Tsutsui H; Mawatari E; Hidaka H; Kumazaki S; Yazaki Y; Takahashi M; Kinoshita O; Ikeda U
Circ J; 2008 May; 72(5):722-8. PubMed ID: 18441450
[TBL] [Abstract][Full Text] [Related]
2. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group.
Hongo M; Kumazaki S; Izawa A; Hidaka H; Tomita T; Yazaki Y; Kinoshita O; Ikeda U
Circ J; 2011; 75(11):2660-7. PubMed ID: 21857142
[TBL] [Abstract][Full Text] [Related]
3. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
Lunder M; Janić M; Jug B; Sabovič M
Eur J Intern Med; 2012 Apr; 23(3):261-6. PubMed ID: 22385885
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
5. [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
Widimský J; Hulínský V; Balazovjech I; Lánská V
Vnitr Lek; 1999 Apr; 45(4):210-6. PubMed ID: 11045181
[TBL] [Abstract][Full Text] [Related]
6. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
[TBL] [Abstract][Full Text] [Related]
7. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment.
Riegger G; Abletshauser C; Ludwig M; Schwandt P; Widimsky J; Weidinger G; Welzel D
Atherosclerosis; 1999 May; 144(1):263-70. PubMed ID: 10381299
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Leitersdorf E; Muratti EN; Eliav O; Peters TK
Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
Spieker LE; Noll G; Hannak M; Lüscher TF
J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW
Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism.
Wittke R
Sports Med; 1999 May; 27(5):329-35. PubMed ID: 10368879
[TBL] [Abstract][Full Text] [Related]
13. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease.
Rothe G; Herr AS; Stöhr J; Abletshauser C; Weidinger G; Schmitz G
Atherosclerosis; 1999 May; 144(1):251-61. PubMed ID: 10381298
[TBL] [Abstract][Full Text] [Related]
14. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
15. Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Fanghänel G; Espinosa J; Olivares D; Sánchez L; Morales M; Martínez L; Macías G; Valdés E; Hernández G
Am J Cardiol; 1995 Jul; 76(2):57A-61A. PubMed ID: 7604800
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.
Ichihara A; Hayashi M; Ryuzaki M; Handa M; Furukawa T; Saruta T
Nephrol Dial Transplant; 2002 Aug; 17(8):1513-7. PubMed ID: 12147804
[TBL] [Abstract][Full Text] [Related]
17. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
Ballantyne CM; Herd JA; Ferlic LL; Dunn JK; Farmer JA; Jones PH; Schein JR; Gotto AM
Circulation; 1999 Feb; 99(6):736-43. PubMed ID: 9989957
[TBL] [Abstract][Full Text] [Related]
18. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
Westphal S; Abletshauser C; Luley C
Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
[TBL] [Abstract][Full Text] [Related]
20. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
